Connect Biopharma shares surge 10.57% intraday after Phase 3 rademikibart atopic dermatitis study results announced for AAD 2026 presentation supporting China NDA.

Connect Biopharma surged 10.57% intraday after announcing that partner Simcere’s Phase 3 trial of rademikibart in moderate-to-severe atopic dermatitis will be presented at the AAD Annual Meeting in March 2026. The data, described as a "strong basis" for Simcere’s pending New Drug Application (NDA) in China, also highlighted rademikibart’s differentiated safety and efficacy profile, supporting future development in atopic dermatitis outside China. Concurrently, a March 2026 corporate presentation emphasized rademikibart’s superior pharmacology compared to dupilumab, including faster onset of action and improved safety, with Phase 2 studies in acute asthma and COPD advancing. The dual catalysts—regulatory progress in China and competitive differentiation—driven optimism about rademikibart’s commercial potential, fueling the sharp intraday rally.